Logo image of FHTX

FOGHORN THERAPEUTICS INC (FHTX) Stock Fundamental Analysis

NASDAQ:FHTX - US3441741077 - Common Stock

5.56 USD
+0.52 (+10.32%)
Last: 8/22/2025, 8:06:56 PM
5.56 USD
0 (0%)
After Hours: 8/22/2025, 8:06:56 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FHTX. FHTX was compared to 549 industry peers in the Biotechnology industry. FHTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FHTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FHTX has reported negative net income.
In the past year FHTX has reported a negative cash flow from operations.
In the past 5 years FHTX always reported negative net income.
FHTX had negative operating cash flow in 4 of the past 5 years.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

With a decent Return On Assets value of -33.33%, FHTX is doing good in the industry, outperforming 63.21% of the companies in the same industry.
Industry RankSector Rank
ROA -33.33%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FHTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FHTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FHTX has more shares outstanding
FHTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FHTX has an Altman-Z score of -3.69. This is a bad value and indicates that FHTX is not financially healthy and even has some risk of bankruptcy.
FHTX's Altman-Z score of -3.69 is in line compared to the rest of the industry. FHTX outperforms 46.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.69
ROIC/WACCN/A
WACC9.76%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

FHTX has a Current Ratio of 2.62. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
FHTX has a Current ratio of 2.62. This is in the lower half of the industry: FHTX underperforms 68.67% of its industry peers.
A Quick Ratio of 2.62 indicates that FHTX has no problem at all paying its short term obligations.
The Quick ratio of FHTX (2.62) is worse than 66.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 2.62
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.97% over the past year.
The Revenue for FHTX has decreased by -31.30% in the past year. This is quite bad
Measured over the past years, FHTX shows a very strong growth in Revenue. The Revenue has been growing by 157.75% on average per year.
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%9.71%

3.2 Future

The Earnings Per Share is expected to grow by 14.68% on average over the next years. This is quite good.
Based on estimates for the next years, FHTX will show a quite strong growth in Revenue. The Revenue will grow by 19.01% on average per year.
EPS Next Y16.81%
EPS Next 2Y9.77%
EPS Next 3Y4.86%
EPS Next 5Y14.68%
Revenue Next Year-3.61%
Revenue Next 2Y1.02%
Revenue Next 3Y9.77%
Revenue Next 5Y19.01%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FHTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.77%
EPS Next 3Y4.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FHTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (8/22/2025, 8:06:56 PM)

After market: 5.56 0 (0%)

5.56

+0.52 (+10.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners72.41%
Inst Owner Change1.36%
Ins Owners8.07%
Ins Owner Change0%
Market Cap314.31M
Analysts84.62
Price Target11.9 (114.03%)
Short Float %1.97%
Short Ratio7.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.74%
Min EPS beat(2)14.04%
Max EPS beat(2)23.44%
EPS beat(4)4
Avg EPS beat(4)19.64%
Min EPS beat(4)10.09%
Max EPS beat(4)30.99%
EPS beat(8)8
Avg EPS beat(8)25.28%
EPS beat(12)11
Avg EPS beat(12)16.89%
EPS beat(16)11
Avg EPS beat(16)7.4%
Revenue beat(2)2
Avg Revenue beat(2)7.18%
Min Revenue beat(2)0.34%
Max Revenue beat(2)14.02%
Revenue beat(4)3
Avg Revenue beat(4)-6.68%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)20.77%
Revenue beat(8)6
Avg Revenue beat(8)32.27%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)8
Avg Revenue beat(16)19.76%
PT rev (1m)10.36%
PT rev (3m)10.36%
EPS NQ rev (1m)9.93%
EPS NQ rev (3m)2.49%
EPS NY rev (1m)0%
EPS NY rev (3m)2.48%
Revenue NQ rev (1m)2.94%
Revenue NQ rev (3m)5.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0.43
BVpS-1.38
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.42%
Cap/Sales 3.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 2.62
Altman-Z -3.69
F-Score1
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y16.81%
EPS Next 2Y9.77%
EPS Next 3Y4.86%
EPS Next 5Y14.68%
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%9.71%
Revenue Next Year-3.61%
Revenue Next 2Y1.02%
Revenue Next 3Y9.77%
Revenue Next 5Y19.01%
EBIT growth 1Y3.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.79%
EBIT Next 3Y5.8%
EBIT Next 5YN/A
FCF growth 1Y19.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.42%
OCF growth 3YN/A
OCF growth 5YN/A